Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

PIPE-307

Small molecule · developed by Contineum Therapeutics

Phase 1 Most advanced trial (none active)
CTNM Developer
1 Registered trials

What is PIPE-307?

PIPE-307 is an oral small molecule studied in multiple sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Contineum Therapeutics (CTNM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04941781 Phase 1 Multiple Sclerosis Completed CTNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Sclerosis

More from Contineum Therapeutics

PIPE-505 Phase 1/2 PIPE-791 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CTNM page.

Follow CTNM, the company behind PIPE-307

See CTNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTNM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.